# Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

> **NCT07030140** · PHASE2 · RECRUITING · sponsor: **Jinbo Yue** · enrollment: 38 (estimated)

## Conditions studied

- Cholangiocarcinoma
- Hilar Cholangiocarcinoma
- Bile Duct Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)
- **DRUG:** Tislelizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin or Oxaliplatin

## Key facts

- **NCT ID:** NCT07030140
- **Lead sponsor:** Jinbo Yue
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030140, "Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07030140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*